NRNP 6821 Week 9 Evidence Appraisal Example

Course	NRNP 6821 Management of Chronic Pediatric Populations
Week	Week 9
Paper type	Evidence appraisal paper
Length	About 840 words, 6 pages
Format	APA 7 student paper
School	Walden University
Program	Master of Science in Nursing (MSN)
Updated	October 2026

Free sample paper for NRNP 6821 Week 9

Evidence Appraisal: The 2004 Pediatric Migraine Prevention Parameter Against the 2019 Guideline Update and the CHAMP Trial, for a 13-Year-Old With Frequent Migraine

Student Name

College of Nursing, Walden University

NRNP 6821: Management of Chronic Pediatric Populations

Instructor Name

Month Day, Year

What this page is doingThe title names both versions and the trial that moved the field. An appraisal that tests a claim against a superseded guideline, or never says which version it used, loses the marks this week is built around.

Evidence Appraisal: The 2004 Pediatric Migraine Prevention Parameter Against the 2019 Guideline Update and the CHAMP Trial, for a 13-Year-Old With Frequent Migraine

The Clinical Frame

Composite patient: a 13-year-old girl with migraine without aura. Her headache diary, kept for three months, shows 8, 9, and 7 headache days per month, with 3 to 4 school absences a month and a pediatric migraine disability score in the moderate range. Her acute treatment helps within two hours on most days. Her parents ask about a daily medicine to prevent headaches, and they bring a printout from an older clinic handout that cites the 2004 practice parameter.

The Claim, Stated Precisely

The claim under appraisal, in paraphrase from the 2004 American Academy of Neurology practice parameter on pharmacological treatment of migraine in children and adolescents: for preventive therapy, flunarizine is probably effective; data for cyproheptadine, amitriptyline, divalproex, topiramate, and levetiracetam are insufficient; data for propranolol and trazodone are conflicting; and pizotifen, nimodipine, and clonidine did not show efficacy (Lewis et al., 2004). The parameter's conclusion was that, apart from flunarizine, which is not available in the United States, the evidence did not support recommending any preventive medication.

What Stood Behind It

The 2004 authors reviewed 166 articles and evaluated 12 preventive agents (Lewis et al., 2004). Most preventive studies available then were small, many were open-label or not placebo-controlled, and few enrolled only children. The authors themselves noted a disappointing lack of randomized, masked trials for a problem so common in children. Placebo response was not a central theme in the 2004 conclusions, because few placebo-controlled pediatric trials existed to measure it. The parameter was cautious because its evidence was thin, not because it had tested the drugs and found them wanting.

The Version in Force

The current pediatric guidance is the 2019 practice guideline update issued jointly by the AAN and the AHS, drawing on literature from 2003 to August 2017; the 2004 parameter is now marked as retired, and I found no later pediatric version at the time of writing. The 2019 update found that children and adolescents receiving topiramate and cinnarizine are probably more likely than those receiving placebo to have fewer headaches, that propranolol is possibly effective, and that evidence was insufficient for divalproex, onabotulinumtoxinA, amitriptyline alone, nimodipine, and flunarizine. Its central finding is that most randomized trials of preventive medicines in pediatric migraine have not shown superiority to placebo. It recommends counseling on lifestyle and behavioral factors, managing coexisting conditions, and shared decision-making that includes the limits of the evidence (Oskoui et al., 2019).

Currency was checked before relying on it. A search of the indexed literature for newer guidance on preventive treatment of migraine found a 2026 guideline from the same two organizations, but it addresses adults only and does not replace the pediatric update. A guideline written for adults cannot be carried over to a 13-year-old without asking whether its trials enrolled anyone her age, and its recommendations are framed for adults. The pediatric update therefore remains the version this appraisal tests the older claim against, and the note records that the check was made and when.

The trial that most shaped that finding is CHAMP. In 361 children and adolescents aged 8 to 17, amitriptyline, topiramate, and placebo were compared over 24 weeks. A reduction of 50% or more in headache days occurred in 52% on amitriptyline, 55% on topiramate, and 61% on placebo, with no significant differences, and the trial was stopped early for futility; both drugs caused more side effects than placebo (Powers et al., 2017). The placebo response, larger than either drug's, is itself the lesson. A separate trial found that cognitive behavioral therapy plus amitriptyline reduced headache days more than headache education plus amitriptyline, with 66% compared with 36% reaching a 50% reduction (Powers et al., 2013).

Side by Side

Amitriptyline. 2004: insufficient data. 2019: insufficient evidence alone; more effective with cognitive behavioral therapy than with education. Moved: toward pairing with therapy.

Topiramate. 2004: insufficient data. 2019: probably effective compared with placebo, though CHAMP showed no advantage. Moved: from unknown to uncertain.

Propranolol. 2004: conflicting. 2019: possibly effective. Moved: slightly.

Flunarizine. 2004: probably effective. 2019: insufficient evidence. Moved: downward, and still unavailable in the United States.

Placebo response. 2004: rarely measured. 2019: a central finding. Moved: from background to foreground.

What this page is doingThe table compares the two versions agent by agent, so the direction of change can be read directly.

Current Standing

The 2004 claim was not wrong for its time. Its caution about most preventive medicines has largely held; what changed is the reason. In 2004, the evidence was too thin to say; by 2019, better trials had been done, and most did not beat placebo. For this girl, the current guidance supports a shared decision in which her family hears that a daily medicine may help less than they expect, that placebo response in trials was high, and that behavioral treatment, sleep, hydration, and regular meals have evidence of their own. If they choose a medicine, the choice is made with those limits stated, and her diary continues so the result can be judged at 3 months.

References

Lewis, D., Ashwal, S., Hershey, A., Hirtz, D., Yonker, M., & Silberstein, S. (2004). Practice parameter: Pharmacological treatment of migraine headache in children and adolescents. Neurology, 63(12), 2215-2224. https://doi.org/10.1212/01.WNL.0000147332.41993.90

Oskoui, M., Pringsheim, T., Billinghurst, L., Potrebic, S., Gersz, E. M., Gloss, D., Holler-Managan, Y., Leininger, E., Licking, N., Mack, K., Powers, S. W., Sowell, M., Victorio, M. C., Yonker, M., Zanitsch, H., & Hershey, A. D. (2019). Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention. Neurology, 93(11), 500-509. https://doi.org/10.1212/WNL.0000000000008105

Powers, S. W., Coffey, C. S., Chamberlin, L. A., Ecklund, D. J., Klingner, E. A., Yankey, J. W., Korbee, L. L., Porter, L. L., & Hershey, A. D. (2017). Trial of amitriptyline, topiramate, and placebo for pediatric migraine. The New England Journal of Medicine, 376(2), 115-124. https://doi.org/10.1056/NEJMoa1610384

Powers, S. W., Kashikar-Zuck, S. M., Allen, J. R., LeCates, S. L., Slater, S. K., Zafar, M., Kabbouche, M. A., O'Brien, H. L., Shenk, C. E., Rausch, J. R., & Hershey, A. D. (2013). Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: A randomized clinical trial. JAMA, 310(24), 2622-2630. https://doi.org/10.1001/jama.2013.282533

NRNP 6821 Week 9 instructions, in plain terms

NRNP 6821 Week 9 centers on testing one management claim against the current evidence. You frame the clinical question, state the claim precisely, trace its original evidence, identify the current guideline version, compare the sources and state where the claim stands now. Faculty check currency first, so a superseded guideline loses marks. Cite each guideline and trial in APA 7 with years. An appraisal tool may be used but is not always required. The paper need not tell the reader what the child should take. Nonpharmacologic options, such as cognitive behavioral therapy, may be noted where evidence supports them. Report the trial's population, outcome and result in a sentence each.

How this NRNP 6821 Week 9 example is built

A comparison table sits at the center of roughly five pages. A short clinical frame introduces a composite thirteen-year-old with frequent migraines, a headache diary kept over three months and a family asking about prevention. The claim under appraisal is stated in paraphrase with its source identified. The appraisal then characterizes the evidence behind it: study designs, populations, placebo response, and whether trials in children existed when it was written. The current guideline is presented next, with the version identified and its central finding stated: most preventive medications studied in children have not clearly outperformed placebo, and prevention is a shared decision that also weighs lifestyle and behavioral approaches. The table sets the two sources side by side on each point. A conclusion rates the claim's current standing without recommending a treatment.

Where the marks sit in the NRNP 6821 Week 9 rubric

Currency is checked first. An appraisal that tests a claim against a superseded guideline, or never identifies which version it used, forfeits the very marks this assignment exists to test. Next comes fairness: papers that dismiss the older source as simply wrong, without assessing what evidence it had, show less appraisal than one that explains how the field moved. Claims stated vaguely, as 'medication helps migraine', cannot be tested and cost the paper its footing. Placebo response is expected to be addressed, since it is central to why pediatric prevention trials disappointed. A verdict that turns into a treatment recommendation oversteps the task. Table completeness, the citation of whatever appraisal tool was used, and reference formatting account for the rest.

Common NRNP 6821 Week 9 mistakes, and how to avoid them

Appraisals lose the most when they test a claim against an outdated guideline or never say which version they used. Name the current version and its year. Another common gap is reporting CHAMP without its result: no benefit over placebo. State it. Writers also blur what a trial shows with what a guideline recommends. Keep them separate. Avoid concluding that preventives never help; the evidence is about these drugs in this age group. Mention the high placebo response. Keep the headache diary numbers consistent. Close with how the evidence would shape a conversation with her family. Writers also forget to say what the appraisal means for this girl's family, such as a trial of lifestyle measures and therapy. Add it.

Get a NRNP 6821 Week 9 example written to your instructions

Provide the Week 9 prompt and rubric along with the claim or guideline your section assigned, and the appraisal holds that claim up to whichever guideline version now applies. There is no fee for your first sample, which returns in 24 to 48 hours. The thirteen-year-old and her headache diary were written for illustration; no family's records appear.

More NRNP 6821 papers and MSN samples

NRNP 6821 Week 9 questions, answered

Which appraisal tool does the example use?

It uses a structured approach close to the widely taught critical appraisal checklists, asking about design, population, outcome, comparator and applicability, and it cites the checklist it follows. Many sections name a specific tool, such as a CASP checklist or the AGREE II instrument for guidelines. When your prompt names one, the appraisal is organized under that tool's headings instead.

Does the appraisal say whether the child should take a preventive?

No. It rates the claim's standing against current guidance and stops there. Whether any child starts prevention is a shared decision between a family and the treating clinician, which is itself a point the current guideline emphasizes. The example describes what the evidence supports in general terms and leaves individual treatment choices, drugs and doses out of the paper entirely.

How is the guideline version identified?

By the issuing organizations, the title and its publication status as stated on the document, and the appraisal checks whether any update or reaffirmation has followed. The week tests exactly this, so the example states it in the first paragraph where the guideline appears. Faculty commonly deduct for citing a guideline without confirming that no later version has replaced it.

Where can I find a free NRNP 6821 Week 9 sample paper?

The pediatric migraine prevention appraisal is reproduced here with the claim, the 2004 parameter, the 2019 update, the CHAMP trial side by side and current standing.

Which drugs are named in the NRNP 6821 Week 9 claim?

Amitriptyline and topiramate, tested against the 2019 AAN and AHS pediatric migraine prevention guideline.